Related Experiment Video
Updated: Apr 11, 2026

07:32
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
2.2K
Cellular prognostic markers in hepatocellular carcinoma
Future Oncology (London, England)
|June 5, 2015
Summary
Hepatocellular carcinoma (HCC), a major global cancer linked to chronic hepatitis, involves complex tumor microenvironments. Intratumoral cells influence HCC progression, but none are validated for routine prognosis.
Area of Science:
- Oncology
- Immunology
- Hepatology
Background:
- Hepatocellular carcinoma (HCC) is a leading cause of cancer death globally.
- HCC is strongly associated with chronic hepatitis B (HBV) and hepatitis C (HCV) infections.
- The tumor microenvironment significantly impacts HCC progression, invasion, angiogenesis, and metastasis.
Purpose of the Study:
- To review the current state of research on tumor-infiltrating cells in HCC.
- To highlight the correlation between specific immune cells and HCC clinical prognosis.
- To identify potential biomarkers for HCC diagnosis and prognosis from the tumor microenvironment.
Main Methods:
- Systematic literature review of studies investigating the tumor microenvironment in HCC.
- Analysis of research correlating intratumoral cell infiltration with HCC progression and patient outcomes.
- Evaluation of the diagnostic and prognostic potential of identified cells.
Main Results:
- Numerous studies demonstrate a strong link between intratumoral cell infiltration and HCC clinical prognosis.
- Specific immune cells within the tumor microenvironment influence tumor growth, invasion, angiogenesis, and metastasis.
- Currently, no single cell type within the HCC microenvironment is validated for routine clinical use.
Conclusions:
- The tumor microenvironment, particularly infiltrating cells, is crucial for understanding HCC progression.
- Further research is needed to validate specific cellular biomarkers for HCC diagnosis and prognosis.
- Targeting tumor-infiltrating cells may offer future therapeutic strategies for HCC.

